阿斯利康中国以及阿斯利康两位前高管，被深圳检方提起公诉

Core Viewpoint - AstraZeneca faces legal challenges in China, including allegations of unlawful collection of personal information and illegal trade, involving former executives and employees [1][2][3] Legal Issues - The Shenzhen Intermediate People's Court is consolidating related cases, with a court date yet to be determined [1][3] - AstraZeneca's former global executive vice president and China president, Wang Lei, is reportedly the individual involved in the allegations [3] - The company has not been charged with obtaining illegal benefits from the unlawful collection of personal information or medical insurance fraud [3] Financial Implications - AstraZeneca China received a notice regarding unpaid import taxes totaling RMB 24 million (approximately USD 3.5 million) related to specific drugs [2] - The company voluntarily prepaid the full amount as compensation, but could face fines of one to five times the unpaid import taxes if found liable for illegal trade [2] Market Performance - In 2025, AstraZeneca's revenue from the Chinese market reached USD 6.654 billion, a 4% increase year-over-year, accounting for 11% of the company's global revenue [3] - Despite achieving a record high in revenue, the growth rate in China was lower than the global average of 8% [3] Future Investments - AstraZeneca plans to invest over RMB 100 billion (approximately USD 15 billion) in China by 2030 to expand its pharmaceutical production and R&D capabilities [4]